OncoMatch/Clinical Trials/NCT06793917
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Is NCT06793917 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for gastric cancer.
Treatment: Tislelizumab · Oxaliplatin · Levo-Leucovorin · 5-fluorouracil · Paclitaxel — To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS≥1
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Biomarker criteria
Required: PD-L1 (CD274) CPS testing required (testing required; no eligibility threshold specified)
Have a known PD-L1 CPS/MMR (or MSI) /HER2(FISH) test result, or have sufficient samples for relevant testing
Required: MMR testing required (testing required; no eligibility threshold specified)
Have a known PD-L1 CPS/MMR (or MSI) /HER2(FISH) test result, or have sufficient samples for relevant testing
Required: MSH2 testing required (testing required; no eligibility threshold specified)
Have a known PD-L1 CPS/MMR (or MSI) /HER2(FISH) test result, or have sufficient samples for relevant testing
Required: HER2 (ERBB2) testing required (testing required; no eligibility threshold specified)
Have a known PD-L1 CPS/MMR (or MSI) /HER2(FISH) test result, or have sufficient samples for relevant testing
Excluded: HER2 (ERBB2) overexpression
Her2-positive (IHC 3+ or 2+/FISH+) patients
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: perioperative chemotherapy, six months after fluorouracil alone or one year after oxaliplatin or a combination of taxoid and fluorouracil can be included
No previous chemotherapy (perioperative chemotherapy, six months after fluorouracil alone or one year after oxaliplatin or a combination of taxoid and fluorouracil can be included)
Cannot have received: radiotherapy
No previous...radiotherapy
Cannot have received: immunotherapy
No previous...immunotherapy
Lab requirements
Blood counts
hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); leucopenia count of ≥4.0×10^9/L; platelet count of ≥100×10^9/L
Kidney function
creatinine (Cr) of ≤ 1.5 UNL; creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault)
Liver function
total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis
Cardiac function
normal electrocardiogram results and no history of congestive heart failure
With normal marrow, liver and renal function: a hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); a leucopenia count of ≥4.0×10^9/L; a platelet count of ≥100×10^9/L; a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis. With normal electrocardiogram results and no history of congestive heart failure.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06793917 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 CPS testing required is a required biomarker for enrollment.
Does this trial require MMR?
Yes, MMR testing required is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 testing required is a required biomarker for enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify